Cargando…
Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459903/ https://www.ncbi.nlm.nih.gov/pubmed/37631283 http://dx.doi.org/10.3390/pharmaceutics15082069 |
_version_ | 1785097523586662400 |
---|---|
author | Martin Mena, Anthony Négrier, Laura Treizebré, Anthony Guilbert, Marie Bonnaire, Lucille Daniau, Valentine Leba Bonki, Gabie Odou, Pascal Genay, Stéphanie Décaudin, Bertrand |
author_facet | Martin Mena, Anthony Négrier, Laura Treizebré, Anthony Guilbert, Marie Bonnaire, Lucille Daniau, Valentine Leba Bonki, Gabie Odou, Pascal Genay, Stéphanie Décaudin, Bertrand |
author_sort | Martin Mena, Anthony |
collection | PubMed |
description | Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strategies have never been compared directly (and particularly in terms of the particulate load and drug mass flow rate) under standardized conditions. The objective of the present in vitro study was to evaluate the impact of various strategies for preventing incompatibility between simultaneously infused vancomycin and piperacillin/tazobactam. Methods: An in-line filter, a dilute vancomycin solution (5 mg/mL), and an alternative saline administration line were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. The antibiotic concentration was measured in an HPLC-UV assay. Result: The use of an in-line filter and an alternative saline administration route did not significantly reduce the particulate load caused by vancomycin-piperacillin/tazobactam incompatibility. Dilution of the vancomycin solution was associated with a significantly lower particulate load and maintenance of the vancomycin mass flow rate. Discussion: It is important to systematically compare the efficacy of strategies for preventing drug incompatibility. The use of diluted vancomycin solution gave the best results in the case of vancomycin-piperacillin/tazobactam incompatibility. |
format | Online Article Text |
id | pubmed-10459903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104599032023-08-27 Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility Martin Mena, Anthony Négrier, Laura Treizebré, Anthony Guilbert, Marie Bonnaire, Lucille Daniau, Valentine Leba Bonki, Gabie Odou, Pascal Genay, Stéphanie Décaudin, Bertrand Pharmaceutics Article Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strategies have never been compared directly (and particularly in terms of the particulate load and drug mass flow rate) under standardized conditions. The objective of the present in vitro study was to evaluate the impact of various strategies for preventing incompatibility between simultaneously infused vancomycin and piperacillin/tazobactam. Methods: An in-line filter, a dilute vancomycin solution (5 mg/mL), and an alternative saline administration line were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. The antibiotic concentration was measured in an HPLC-UV assay. Result: The use of an in-line filter and an alternative saline administration route did not significantly reduce the particulate load caused by vancomycin-piperacillin/tazobactam incompatibility. Dilution of the vancomycin solution was associated with a significantly lower particulate load and maintenance of the vancomycin mass flow rate. Discussion: It is important to systematically compare the efficacy of strategies for preventing drug incompatibility. The use of diluted vancomycin solution gave the best results in the case of vancomycin-piperacillin/tazobactam incompatibility. MDPI 2023-08-01 /pmc/articles/PMC10459903/ /pubmed/37631283 http://dx.doi.org/10.3390/pharmaceutics15082069 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Martin Mena, Anthony Négrier, Laura Treizebré, Anthony Guilbert, Marie Bonnaire, Lucille Daniau, Valentine Leba Bonki, Gabie Odou, Pascal Genay, Stéphanie Décaudin, Bertrand Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility |
title | Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility |
title_full | Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility |
title_fullStr | Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility |
title_full_unstemmed | Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility |
title_short | Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility |
title_sort | evaluation of strategies for reducing vancomycin-piperacillin/tazobactam incompatibility |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459903/ https://www.ncbi.nlm.nih.gov/pubmed/37631283 http://dx.doi.org/10.3390/pharmaceutics15082069 |
work_keys_str_mv | AT martinmenaanthony evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT negrierlaura evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT treizebreanthony evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT guilbertmarie evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT bonnairelucille evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT daniauvalentine evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT lebabonkigabie evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT odoupascal evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT genaystephanie evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility AT decaudinbertrand evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility |